0 CHECKOUT

PRODUCT FILTERS

REGION

373
351
342
318
317

COUNTRY

304
23
18
13
12

PRICE

24
287
483
1,269

PUBLISHED

286
342
752
1,269

PRODUCT TYPE

1,255
12
1
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

Investigation Report on China's Insulin Glargine Market, 2010-2019

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million...

Published:  May 2015
Price:  From

Investigation Report on China's Esomeprazole Market, 2010-2019

The digestive system disease is one of the frequently-occurring diseases. According to statistics of WHO, there are at least 250 million digestive tract patients, mainly suffering from canker. Inhibition...

Published:  May 2015
Price:  From

Investigation Report on China's Celecoxib Market, 2010-2019

Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs...

Published:  June 2015
Price:  From

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis By Product (Corticosteroids, Intravenous Immunoglobulin, Anti-D Immunoglobulin, TPO-RA) And Segment Forecasts To 2020

Global ITP therapeutics market is expected to reach USD 566.37 million by 2020. Introduction of new drugs especially pertaining to TPO-RA and IVIG classes is expected to serve this market as a high...

Published:  December 2014
Price:  From

CIS Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs, Recombinant Insulin) Analysis and Segment Forecasts to 2020

The CIS market for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%. The presence of an extensive pipeline portfolio of products exhibiting higher...

Published:  July 2014
Price:  From

Latin America (Brazil, Argentina, Chile, Mexico, Colombia, Venezuela) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs, Recombinant) Analysis and Segment Forecasts to 2020

The Latin America market for Insulin is expected to reach USD 3,760.7 million by 2020. Growing prevalence of diabetes (type I and type II) coupled with government initiatives to develop insulin in markets...

Published:  June 2014
Price:  From

Insulin Market Analysis by Product (Fast Acting, Short Acting, Intermediate Acting, Pre-Mix and Long Acting), by Segments (Insulin Analogs and Human Recombinant Insulin), by Application (Type I and Type II Diabetes) and Segment Forecasts to 2020

The global market for insulin is expected to reach USD 47.54 billion by 2020. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as...

Published:  April 2014
Price:  From

Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs & Recombinant Insulin) Analysis and Segment Forecasts to 2020

The Asia Pacific market for Insulin is expected to reach USD 15.04 billion by 2020. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging...

Published:  May 2014
Price:  From

Global Multiple Sclerosis Drugs Market 2014-2018

About Multiple Sclerosis and Disease Types Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath...

Published:  August 2014
Price:  From

Insulin Market in China 2014-2018

About Insulin Insulin is a hormone produced in the pancreas. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates...

Published:  October 2014
Price:  From

Therapeutic Class Overview : Psoriasis – Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients' pain, function, and quality of life Approved biologics...

Published:  February 2014
Price:  From

Global Rheumatoid Arthritis Drugs Market 2014-2018

About Rheumatoid Arthritis RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation...

Published:  July 2014
Price:  From

Global HIV Infection Drug Market & Pipeline Insight

The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe It has been estimated that the death rate reduced from 2 3 million in...

Published:  August 2014
Price:  From

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world According to UNAIDS, death...

Published:  March 2014
Price:  From

Anacor Pharmaceuticals' AN2728 - novel topical PDE4 inhibitor for atopic dermatitis

Anacor's AN2728 is a boron-containing topically administered phosphodiesterase 4 (PDE4) inhibitor that suppresses the release of TNF-alpha, IL-12 and other inflammatory cytokines The compound is entering...

Published:  January 2014
Price:  From

Therapy Class Overview : Rituximab biosimilar

Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which...

Published:  October 2013
Price:  From

CAS Hydroxychloroquine World Consumption Report

This CAS Hydroxychloroquine World Consumption Report provides data on the net consumption of CAS 118-42-3 - Hydroxychloroquine Substance(s) in each of the countries listed. The Substance(s) covered...

Published:  February 2016
Price: 

CAS Hydroxychloroquine sulfate World Consumption Report

This CAS Hydroxychloroquine sulfate World Consumption Report provides data on the net consumption of CAS 747-36-4 - Hydroxychloroquine sulfate Substance(s) in each of the countries listed. The Substance(s)...

Published:  February 2016
Price: 

CAS Betamethasone 21-phosphate disodium World Consumption Report

This CAS Betamethasone 21-phosphate disodium World Consumption Report provides data on the net consumption of CAS 151-73-5 - Betamethasone 21-phosphate disodium Substance(s) in each of the countries...

Published:  February 2016
Price: 

CAS Azathioprine World Consumption Report

This CAS Azathioprine World Consumption Report provides data on the net consumption of CAS 446-86-6 - Azathioprine Substance(s) in each of the countries listed. The Substance(s) covered (Azathioprine...

Published:  February 2016
Price: 
Loading Indicator

Our Clients